Nelson Jen An Chao

Journal article J Hematother Stem Cell Res · August 2002 Featured Publication Nonmyeloablative allogeneic stem cell transplantation (NMSCT) may destroy some malignancies through a graft-versus-tumor (GVT) effect, but tumor relapse and viral reactivation remain challenges for which immunizations may be helpful. Dendritic cells (DC), ... Full text Link to item Cite

Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process.

Journal article Blood · May 1, 2002 Featured Publication In this study, we investigated the possibility of selective depletion of donor alloantigen-specific T cells from C57BL/6 (H-2(b)) mice to prevent graft-versus-host disease (GVHD). These cells were first activated with irradiated BALB/c (H-2(d)) host spleen ... Full text Link to item Cite

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.

Journal article Leuk Lymphoma · May 2002 Featured Publication Twenty-three adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL) were treated for up to 12 weeks with the anti-CD52 monoclonal antibody alemtuzumab. Patients were a median of six years from diagnos ... Full text Link to item Cite

Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF.

Journal article Cytokine · April 7, 2002 Featured Publication Treatment with myeloablative chemotherapy and autologous peripheral blood stem cell (PBSC) transplantation followed by vaccination with autologous dendritic cells (DCs) treated with tumor antigens is a promising therapeutic strategy for several types of ca ... Full text Link to item Cite

Addition of a second, different allogeneic graft accelerates white cell and platelet engraftment after T-cell-depleted bone marrow transplantation.

Journal article Blood · March 15, 2002 Featured Publication Significant delays in engraftment and lymphoid recovery are the 2 major challenges in cord blood transplantation. The cause for this delay is presumed to be the low numbers of hematopoietic precursors found in one unit of cord blood. One approach to increa ... Full text Link to item Cite

Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model.

Journal article Transplantation · January 15, 2002 Featured Publication BACKGROUND: PG490-88, a semisynthetic derivative of a novel compound PG490 (triptolide) purified from a Chinese herb (Tripterygium wilfordii Hook F), is effective in prevention of murine graft-versus-host disease (GVHD). METHODS: PG490-88 was administrated ... Full text Link to item Cite

Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells.

Journal article Biol Blood Marrow Transplant · 2002 Featured Publication T-cell recovery following myeloablative preparatory regimens and cord blood transplantation in adult patients gen erally occurs between 1 and 3 years following allogeneic bone marrow transplantation. T-cell reconstitution may involve thymic education of do ... Full text Link to item Cite

A comparison of murine T-cell-depleted adult bone marrow and full-term fetal blood cells in hematopoietic engraftment and immune reconstitution.

Journal article Blood · January 1, 2002 Featured Publication Umbilical cord blood has been increasingly used as a source of hematopoietic stem cells. A major area of concern for the use of cord blood transplantation is the delay in myeloid and lymphoid recovery. To directly compare myeloid and lymphoid recovery usin ... Full text Link to item Cite

Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen.

Journal article Blood · December 1, 2001 Featured Publication Reduction in the toxicity of allogeneic transplantation with nonmyeloablative induction regimens has expanded the scope of practice to older and more debilitated patients. However, the limited availability of matched sibling donors requires that alternativ ... Full text Link to item Cite

Acute graft-vs-host disease: pathobiology and management.

Journal article Exp Hematol · March 2001 Featured Publication Acute graft-vs-host disease (GVHD) is a major obstacle to safe allogeneic hematopoietic stem cell transplantation (HSCT), leading to a significant morbidity and mortality. GVHD occurs when transplanted donor T lymphocytes react to foreign host cells. It ca ... Full text Link to item Cite

High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial.

Journal article Blood · January 15, 2001 Featured Publication Advanced stage follicular small cleaved and mixed cell lymphoma is characterized by relapse from remission and survival ranging from 6 to 12 years. Because young patients have the greatest compromise in longevity, the efficacy and toxicity of high-dose rad ... Full text Link to item Cite

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.

Journal article Biol Blood Marrow Transplant · 2001 Featured Publication MSL-109 is a monoclonal antibody specific to the cytomegalovirus (CMV) glycoprotein H with high neutralizing capacity. In a prospective, randomized, double-blind study, allogeneic hematopoietic stem cell transplantation (HSCT) recipients with positive dono ... Full text Link to item Cite

T-Cell recovery in adults and children following umbilical cord blood transplantation.

Journal article Biol Blood Marrow Transplant · 2001 Featured Publication T-cell reconstitution following allogeneic stem cell transplantation may involve thymic education of donor-derived precursors or peripheral expansion of mature T cells transferred in the graft. T cell-receptor excision circles (sjTRECs) are generated withi ... Full text Link to item Cite

Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion.

Journal article Transplantation · November 27, 2000 Featured Publication BACKGROUND: PG490-88 is a water soluble, semisynthetic derivative of a novel compound PG490 (triptolide) purified from the Chinese herb Tripterygium Wilfordii Hook F. METHODS: PG490-88 was administrated into recipient mice in a model (B10.D2-->BALB/c) of l ... Full text Link to item Cite

Cyclosporin A-related cerebral vasculopathy.

Journal article Bone Marrow Transplant · October 2000 Featured Publication The use of cyclosporin A has been associated with several side-effects, including neurotoxicity. The mechanism of toxicity is not well known. We report two patients treated with cyclosporin A who developed lesions in the cerebral white matter associated wi ... Full text Link to item Cite

Conversion of indwelling chest port catheters to tunneled central venous catheters.

Journal article J Vasc Interv Radiol · October 2000 Featured Publication PURPOSE: To determine the safety and efficacy of the conversion of subcutaneous chest wall infusion ports to tunneled central venous catheters. MATERIALS AND METHODS: During a period of 34 months, 67 patients were referred for conversion of indwelling subc ... Full text Link to item Cite

Progress in graft-versus-host disease.

Journal article J Hematother Stem Cell Res · June 2000 Featured Publication Full text Link to item Cite

PG27, an extract of Tripterygium wilfordii hook f, induces antigen-specific tolerance in bone marrow transplantation in mice.

Journal article Blood · January 15, 2000 Featured Publication PG27, an active fraction purified from an extract of a Chinese herb, Tripterygium wilfordii hook f, was used to prevent graft-versus-host disease (GVHD) in a murine model. Lethally irradiated BALB/c (H-2(d)) recipients of B10.D2 (H-2(d)) donor grafts were ... Link to item Cite

Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support.

Journal article Am J Respir Crit Care Med · January 2000 Featured Publication We closely followed the pulmonary function of 150 consecutive high-risk breast cancer patients who underwent standard induction CAF (cyclophosphamide, doxorubicin, 5-fluorouracil) chemotherapy, followed by randomization to either standard-dose CPB (cycloph ... Full text Link to item Cite

High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.

Journal article Biol Blood Marrow Transplant · 2000 Featured Publication Central nervous system (CNS) involvement by non-Hodgkin's lymphoma (NHL) carries a poor patient prognosis whether it occurs as a primary site of disease or secondarily in patients with systemic disease. In a group of 481 patients undergoing high-dose thera ... Full text Link to item Cite

Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.

Journal article Biol Blood Marrow Transplant · 2000 Featured Publication We have previously demonstrated a decrease in the incidence of acute graft-versus-host disease (GVHD) with the addition of methotrexate (MTX) to cyclosporine (CSP) and prednisone (PSE) chemotherapy in patients with leukemia. We have now completed a prospec ... Full text Link to item Cite

Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.

Journal article Biol Blood Marrow Transplant · 2000 Featured Publication Multiple-cycle high-dose therapy with autologous hematopoietic progenitor cell (AHPC) support has been used to deliver dose-intensive therapy. We have used this approach as well as single-cycle high-dose therapy in treating patients with metastatic breast ... Full text Link to item Cite

Graft-versus-host disease prevention by rapamycin: cellular mechanisms.

Journal article Biol Blood Marrow Transplant · 2000 Featured Publication Understanding the cellular mechanisms that lead to graft-versus-host disease (GVHD) may lead to alternative approaches in the prevention or therapy of this disease process. In this manuscript, we investigated the mechanisms of action of the immunosuppressi ... Full text Link to item Cite

A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.

Journal article Clin Cancer Res · November 1999 Featured Publication High-dose chemotherapy (HDCT) is currently under evaluation for high-risk primary breast cancer (HRPBC), defined by extensive axillary nodal involvement or inflammatory breast carcinoma. Phase II studies of HDCT for HRPBC show that 30-40% of patients event ... Link to item Cite

A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.

Journal article Clin Cancer Res · November 1999 Featured Publication Dose-intensive chemotherapy appears to be important in the treatment of patients with recurrent solid tumors. Expanding upon our prior experience, we report the results of our most recent approach to administering dose-intensive therapy using four cycles o ... Link to item Cite

Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support.

Journal article J Clin Oncol · October 1999 Featured Publication PURPOSE: We performed a retrospective review to determine predictive and prognostic factors in patients with metastatic breast cancer who received induction therapy, and, if they responded to treatment, high-dose chemotherapy. PATIENTS AND METHODS: Patient ... Full text Link to item Cite

Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival.

Journal article Biol Blood Marrow Transplant · 1999 Featured Publication Graft-vs.-host disease (GVHD) is a major predictor of outcome following allogeneic bone marrow transplantation (BMT). For patients alive at day 100 after BMT, the presence or absence of chronic GVHD is one of the most important determinants of survival and ... Full text Link to item Cite

Pathophysiologic mechanisms of acute graft-vs.-host disease.

Journal article Biol Blood Marrow Transplant · 1999 Featured Publication Graft-vs.-host disease (GVHD) remains the major toxicity of allogeneic bone marrow transplantation. Mechanistic studies in experimental animal models provide a better understanding of the complex relationships and cascade of events mediated by cellular and ... Full text Link to item Cite

Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.

Journal article J Clin Oncol · March 1998 Featured Publication PURPOSE: To determine the incidence of myelodysplasia (MDS) and/or acute leukemia (AL) in breast cancer patients after high-dose chemotherapy (HDC) with a single conditioning regimen and autologous bone marrow transplant (ABMT), and analyze the cytogenetic ... Full text Link to item Cite

Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.

Journal article Biol Blood Marrow Transplant · December 1997 Featured Publication Myeloablative therapy followed by allogeneic bone marrow transplantation (BMT) has proven to be curative therapy in patients with hematologic malignancies. Relapse, however, remains a major cause of treatment failure for patients with advanced disease. Dur ... Link to item Cite

Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease.

Journal article Am J Surg Pathol · September 1997 Featured Publication Skin biopsies are commonly performed after allogeneic bone marrow transplantation (BMT) to help establish the origin of a new skin rash in a transplant recipient. Histologic criteria and a grading system for acute graft-versus-host reaction of the skin are ... Full text Link to item Cite

Treatment of non-Hodgkin's lymphoma with high-dose therapy and hematopoietic stem cell support.

Journal article Curr Opin Oncol · September 1997 Featured Publication Standard therapies for advanced low-grade lymphomas are not likely to provide a cure, prompting the use of more aggressive approaches. Patients with low-grade lymphoma who receive high-dose therapy with stem cell support appear to have a prolonged disease- ... Full text Link to item Cite

T helper 2-dominant antilymphoma immune response is associated with fatal outcome.

Journal article Blood · August 15, 1997 Featured Publication The precise role of the endogenous immune system in modulating cancer development remains unclear. Tumor cells are generally thought to be nonimmunogenic because they are of 'self' origin. However, tumor-reactive lymphocytes can be isolated from patients w ... Link to item Cite

Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease.

Journal article Immunol Lett · July 1997 Featured Publication Graft-versus-host disease (GVHD), which occurs when donor T-cells recognize multiple minor host histocompatibility antigens as non-self, presents the major limitation to successful allogeneic bone-marrow transplantation. The synthetic random copolymer of t ... Full text Link to item Cite

Graft-versus-host disease: the viewpoint from the donor T cell.

Journal article Biol Blood Marrow Transplant · April 1997 Featured Publication Link to item Cite

Administration of a CD31-derived peptide delays the onset and significantly increases survival from lethal graft-versus-host disease.

Journal article Blood · February 15, 1997 Featured Publication The CD31 monoclonal antibody, LYP21, binds to the CD31 domain 6 and inhibits the human mixed-lymphocyte reaction (MLR) in a specific and dose-dependent fashion. A synthetic CD31 peptide based on human CD31 epitope (amino acids 551 to 574) recognized by LYP ... Link to item Cite

High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices.

Journal article Blood · February 1, 1997 Featured Publication One hundred nineteen patients with relapsed or refractory Hodgkin's disease (HD) received high-dose therapy followed by autologous hematopoietic progenitor cell transplantation. Three preparatory regimens, selected on the basis of prior therapy and pulmona ... Link to item Cite

Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies.

Journal article J Clin Oncol · January 1997 Featured Publication PURPOSE: To determine the effect of age on the outcome of autologous bone marrow transplantation (ABMT) and/or peripheral-blood progenitor-cell (PBPC) transplantation. PATIENTS AND METHODS: A retrospective analysis was performed on 500 consecutive patients ... Full text Link to item Cite

High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma.

Journal article Cancer · December 15, 1996 Featured Publication BACKGROUND: A number of studies have demonstrated that high dose chemotherapy, with or without radiotherapy, with autologous marrow and/or peripheral blood progenitor cell support can result in improved overall and complete response rates in patients with ... Full text Link to item Cite

Immunomodulatory peptides with high binding affinity for class II MHC molecules for the prevention of graft-versus-host disease.

Journal article Leuk Lymphoma · September 1996 Featured Publication Graft-versus-host disease (GVHD) represents the major barrier to successful allogeneic bone marrow transplantation. Positive and negative selection studies have unequivocally demonstrated that donor T cells are responsible for the induction phase of GVHD. ... Full text Link to item Cite

Polymyositis as a manifestation of chronic graft-versus-host disease.

Journal article Medicine (Baltimore) · September 1996 Featured Publication A syndrome indistinguishable from idiopathic polymyositis occurred in 11 patients as a manifestation of chronic GVHD. All patients had elevation of creatine phosphokinase (CPK). Immunohistology demonstrated the effector cells in the muscle infiltrates as c ... Full text Link to item Cite

A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo.

Journal article Proc Natl Acad Sci U S A · May 14, 1996 Featured Publication Graft-versus-host disease (GVHD) is a T-cell-mediated disease of transplanted donor T cells recognizing host alloantigens. Data presented in this report show, to our knowledge, for the first time that a synthetic copolymer of the amino acids L-Glu, L-Lys, ... Full text Link to item Cite

Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.

Journal article Biol Blood Marrow Transplant · May 1996 Featured Publication Thalidomide has been reported to be an effective agent for the treatment of chronic graft-vs.-host disease (GVHD). To determine its efficacy as a prophylactic agent for the prevention of chronic GVHD, a prospective randomized double-blind study was perform ... Link to item Cite

Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.

Journal article Biol Blood Marrow Transplant · May 1996 Featured Publication The use of high-dose chemotherapy with or without total-body irradiation (TBI) followed by autologous hematopoietic cell transplantation is associated with improved survival for relapsed or refractory non-Hodgkin's lymphoma (NHL). Previous reports comparin ... Link to item Cite

Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease.

Journal article N Engl J Med · February 1, 1996 Featured Publication BACKGROUND: Graft-versus-host disease (GVHD) caused by poorly defined minor (i.e., other than HLA) histocompatibility antigens remains a serious problem in recipients of bone marrow transplants. We sought to determine whether the CD31 adhesion molecule is ... Full text Link to item Cite

Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients.

Journal article Cancer Chemother Pharmacol · 1996 Featured Publication PURPOSE: CCNU (lomustine) and other nitrosourea compounds are rapidly metabolized to alkylating moieties, which are active against various malignancies. In humans, CCNU undergoes biotransformation to the geometric isomers of 4'-hydroxyCCNU. The pharmacokin ... Full text Link to item Cite

Prevention and treatment of graft-versus-host disease.

Journal article Ann N Y Acad Sci · December 29, 1995 Featured Publication Graft-versus-host disease remains a formidable barrier in allogeneic bone marrow transplantation. Studies have shown that effective prophylaxis results in improved overall survival for patients following allogeneic bone marrow transplantation. Various meth ... Full text Link to item Cite

Mobilization of peripheral blood progenitor cells by hematopoietic growth factors.

Journal article Can J Oncol · December 1995 Featured Publication The anti-tumor effect and toxicity of chemotherapeutic agents are dose-related. The dose-response curve for these agents is sigmoidal with a threshold, a lag phase, a linear phase and a plateau phase. The aim of cancer chemotherapy is to exploit the differ ... Link to item Cite

Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.

Journal article Biol Blood Marrow Transplant · December 1995 Featured Publication The use of ganciclovir at the time of cytomegalovirus (CMV) infection but before disease onset has been termed "preemptive" therapy. This preemptive ganciclovir administration has been shown to be an effective method for preventing severe CMV disease after ... Link to item Cite

Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers.

Journal article J Immunol · October 15, 1995 Featured Publication Activation of T cells leading to graft-vs-host disease (GVHD) requires two signaling events: the Ag-specific signal generated through the engagement of the TCR/CD3 complex with antigenic peptide fragments presented by MHC molecules on APCs and the second s ... Link to item Cite

Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.

Journal article Cancer · September 1, 1995 Featured Publication BACKGROUND: Retrospective studies suggest that dose intensity is an important determinant of outcome in the treatment of patients with a variety of malignant diseases such as breast cancer, ovarian cancer, and lymphoma. Unfortunately, these results have no ... Full text Link to item Cite

Does thalidomide affect IL-2 response and production?

Journal article Exp Hematol · August 1995 Featured Publication The exact mechanism of immunosuppression by thalidomide is poorly understood. A common denominator in the pathogenesis of graft-vs.-host disease, graft rejection, reactional lepromatous leprosy, and autoimmune disorders modulated by thalidomide is the acti ... Link to item Cite

Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Journal article Blood · June 1, 1995 Featured Publication Link to item Cite

Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.

Journal article Blood · June 1, 1995 Featured Publication High-dose chemotherapy with or without radiotherapy followed by autologous transplantation of hematopoietic progenitor cells is an effective treatment for patients with high-risk or relapsed non-Hodgkin's lymphoma. Chemotherapy and/or hematopoietic growth ... Link to item Cite

A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma.

Journal article Cancer · March 15, 1995 Featured Publication BACKGROUND: This trial studied the feasibility and efficacy of a new preparatory regimen for autologous bone marrow transplantation for patients with advanced lymphoid malignancies. METHODS: Twenty-one patients with Hodgkin's disease (n = 12) and non-Hodgk ... Full text Link to item Cite

Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules.

Journal article Blood · October 15, 1994 Featured Publication Graft-versus-host disease across minor histocompatibility barriers was induced in two different models by transplanting allogeneic bone marrow and spleen cells into irradiated H-2-compatible recipient mice. In this report, we show that administration of pe ... Link to item Cite

Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation.

Journal article Blood · September 1, 1994 Featured Publication Hematopoietic growth factors have been shown to be effective in reducing the period of neutropenia after autologous bone marrow transplantation (BMT). Initial concerns over potential aggravation of graft-versus-host disease (GVHD) and increase in the incid ... Link to item Cite

Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase.

Journal article Blood · September 1, 1994 Featured Publication Ninety-four consecutive patients with chronic myelogenous leukemia in first clinical chronic phase, median age of 34.0 years (range, 6.8 to 52.4 years), with a histocompatible sibling donor, were treated with fractionated total body irradiation (1,320 cGy) ... Link to item Cite

A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.

Journal article Blood · May 15, 1994 Featured Publication Anemia is a universal finding in patients undergoing autologous bone marrow transplantation (BMT). Effective therapies to increase the number of autologous red blood cells could result in a lower morbidity and mortality associated with red blood cell trans ... Link to item Cite

Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.

Journal article Bone Marrow Transplant · 1994 Featured Publication In 1983, we began a series of clinical trials with the goal of reducing the relapse rate following allogeneic BMT for hematologic malignancies. Because of its anti-leukemic activity, the drug VP-16 was chosen and combined with total body irradiation (TBI). ... Link to item Cite

Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission.

Journal article Blood · November 1, 1993 Featured Publication Ninety-nine consecutive patients with acute leukemia in first complete remission under age 50 (median age 27 years; age range 1 to 47 years) with a histocompatible sibling donor were treated with fractionated total body irradiation (1,320 cGy) and high-dos ... Link to item Cite

Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.

Journal article N Engl J Med · October 21, 1993 Featured Publication BACKGROUND: Acute graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation remains a serious problem. In a clinical trial, we tested the combination of cyclosporine and prednisone with and without methotrexate for the prevention of ... Full text Link to item Cite

The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow.

Journal article Leukemia · October 1993 Featured Publication Cloned colony-stimulating factors have been shown to accelerate myeloid recovery following autologous bone marrow transplantation. Studies with granulocyte-macrophage colony-stimulating factor (GM-CSF) have demonstrated efficacy in accelerating neutrophil ... Link to item Cite

Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma.

Journal article Transplantation · June 1993 Featured Publication Link to item Cite

Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy.

Journal article Blood · April 15, 1993 Featured Publication Hematopoietic growth factors have been used to accelerate engraftment after bone marrow transplantation and to "mobilize" peripheral blood progenitor cells (PBPC). We report on the data in 85 consecutive patients with Hodgkin's disease who were treated in ... Link to item Cite

Extended follow-up in 212 long-term allogeneic bone marrow transplant survivors. Issues of quality of life.

Journal article Transplantation · March 1993 Featured Publication A group of 235 allogeneic marrow recipients were contacted at least one year following their BMT to obtain information on their quality of life; 212 (90%) agreed to participate in this survey. A total of 162 adults and 50 pediatric survivors were interview ... Full text Link to item Cite

Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia.

Journal article Blood · January 15, 1993 Featured Publication Current intensive chemotherapy for acute nonlymphoblastic leukemia (ANLL) results in a complete remission in the majority of patients. Unfortunately, the duration of remission is short and most of the patients will experience a relapse of their underlying ... Link to item Cite

Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow.

Journal article Cancer Chemother Pharmacol · 1993 Featured Publication The methoxymorpholino derivative of doxorubicin (MMDX; FCE 23672) has recently entered clinical trials because of its broad spectrum of preclinical antitumor activity and non-cross-resistance in multidrug-resistant (MDR) tumor models. MMDX is activated in ... Full text Link to item Cite

Graft versus host disease following allogeneic bone marrow transplantation.

Journal article Curr Opin Immunol · October 1992 Featured Publication Graft versus host disease is a major barrier in allogeneic bone marrow transplantation. The associated morbidity and mortality need to be understood and prevented if possible, as the potential indications for bone marrow transplantation continue to broaden ... Full text Link to item Cite

Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model.

Journal article Exp Hematol · October 1992 Featured Publication Cyclosporin (CsA) is a potent modulator of multidrug resistance (MDR) and has been combined with etoposide (VP-16) to purge MDR leukemic cells from human bone marrow (BM) in vitro. We studied the feasibility of this approach in an in vivo model for autolog ... Link to item Cite

Dynamic assessment of quality of life after autologous bone marrow transplantation.

Journal article Blood · August 1, 1992 Featured Publication To determine the quality of life in adult patients after autologous bone marrow transplantation (BMT), we administered a questionnaire to a cohort of patients seen at a single referral-based center. The sample included adults 18 years and older during the ... Link to item Cite

G-CSF and peripheral blood progenitor cells.

Journal article Lancet · June 6, 1992 Featured Publication Link to item Cite

Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells.

Journal article Br J Haematol · June 1992 Featured Publication The multidrug resistance gene mdr1, encoding P-glycoprotein (P-gp), can be expressed at high levels in tumour cells derived from normal tissues with constitutive high expression of this gene. In myelogenous leukaemia, the incidence of increased expression ... Full text Link to item Cite

Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma.

Journal article Ann Intern Med · February 1, 1992 Featured Publication OBJECTIVE: To determine the hemopoietic effects of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients having autologous hemopoietic stem cell transplantation for Hodgkin or non-Hodgkin lymphoma. DESIGN: Placebo or GM-CS ... Full text Link to item Cite

In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation.

Journal article Transfusion · January 1992 Featured Publication The in vitro and in vivo effects of cryopreservation on the cytotoxic activity of murine lymphokine-activated killer (LAK) cells were studied. LAK cells were generated by incubation of spleen lymphocytes of BALB/c mice for 3 days with recombinant interleuk ... Full text Link to item Cite

Purging multidrug resistant cells from bone marrow.

Journal article Prog Clin Biol Res · 1992 Featured Publication Link to item Cite

Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model.

Journal article Prog Clin Biol Res · 1992 Featured Publication Link to item Cite

Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission.

Journal article Blood · October 15, 1991 Featured Publication Fifty-three patients with high-risk acute lymphoblastic leukemia (ALL) under age 50 with a histocompatible sibling donor received high-dose radiochemotherapy followed by allogeneic bone marrow transplantation (BMT). The high-risk factors used to identify t ... Link to item Cite

Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia.

Journal article J Clin Oncol · September 1991 Featured Publication The survival of patients with acute leukemia who do not achieve a remission with primary therapy is very poor. High-dose chemoradiotherapy followed by allogeneic bone marrow transplantation (BMT) has been shown to be effective therapy for patients with acu ... Full text Link to item Cite

Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease.

Journal article J Clin Oncol · September 1991 Featured Publication Alkylating agents used either with or without radiation therapy have been associated with the development of myelodysplastic syndrome (MDS) and acute nonlymphoblastic leukemia (ANLL) after treatment of both malignant and nonmalignant disorders. This report ... Full text Link to item Cite

A combined approach for purging multidrug-resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy.

Journal article Blood · May 1, 1991 Featured Publication Selective removal of malignant cells (purging) from bone marrow (BM) is a concern in autologous BM transplantation (ABMT). Use of vincristine, etoposide, or doxorubicin for purging could be rendered ineffective by the presence of multidrug-resistant (MDR) ... Link to item Cite

Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients.

Journal article Ann Intern Med · January 15, 1991 Featured Publication Full text Link to item Cite

The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.

Journal article Ann Oncol · January 1991 Featured Publication Seventy-seven Hodgkin's disease and non-Hodgkin's lymphoma (NHL) patients received high-dose etoposide in combination with cyclophosphamide and either fractionated total body irradiation (TBI) (n = 28) or carmustine (n = 49) prior to autologous bone marrow ... Full text Link to item Cite

Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow.

Journal article Exp Hematol · December 1990 Featured Publication We studied the effects of two modulators of multidrug resistance (MDR), cyclosporine and verapamil, on the cytotoxicity of etoposide (VP-16) in normal human bone marrow; two human leukemia cell lines, K562 and CEM; their MDR variants, K562/DOX and CEM/VLB; ... Link to item Cite

CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma.

Journal article Blood · October 1, 1990 Featured Publication Eighty-three patients with intermediate- or high-grade non-Hodgkin's lymphoma were treated with CEPP(B) (cyclophosphamide, etoposide [VP-16], procarbazine, and prednisone with or without bleomycin) chemotherapy at Stanford University Medical Center (Stanfo ... Link to item Cite

Assessment of purging with multidrug resistance (MDR) modulators and VP-16: results of long-term marrow culture.

Journal article Exp Hematol · September 1990 Featured Publication We studied the effects of two modulators of multidrug resistance (MDR), cyclosporine and verapamil, on the cytotoxicity of etoposide (VP-16) in normal bone marrow cells. VP-16 was toxic to normal bone marrow at concentrations greater than 50 microM, result ... Link to item Cite

Bone marrow transplantation: what is the question?

Journal article Ann Intern Med · September 1, 1990 Featured Publication Full text Link to item Cite

Bone marrow transplantation from histocompatible sibling donors for patients with acute lymphoblastic leukemia.

Journal article Haematol Blood Transfus · 1990 Featured Publication Full text Link to item Cite

Bone marrow transplantation for hematologic malignancies: the Stanford experience.

Journal article Clin Transpl · 1990 Featured Publication Allogeneic and autologous BMTs are highly effective and successful treatment modalities for selected patients. Use of BMT earlier in the course of disease yields better results when compared to patients with more advanced disease. Recent advances such as u ... Link to item Cite

Bone marrow transplantation. Part II--autologous.

Journal article West J Med · January 1990 Featured Publication Autologous bone marrow transplantation provides an effective form of "rescue" following high-dose therapy used for treating certain malignant diseases. The high doses of radiotherapy or chemotherapy, or both, should allow for greater tumor cell kill if dos ... Link to item Cite

Lymphokine-activated killer cell activity after cryopreservation.

Journal article J Immunol Methods · December 20, 1989 Featured Publication The effect of cryopreservation on the cytotoxic activity of lymphokine-activated killer (LAK) cells was studied. LAK cells were generated by incubating peripheral blood lymphocytes for 3-5 days with recombinant interleukin-2 (rIL-2) and then cryopreserved ... Full text Link to item Cite

Bone marrow transplantation. Part I--Allogeneic.

Journal article West J Med · December 1989 Featured Publication Major progress in experimental and clinical research has made allogeneic bone marrow transplantation a highly effective therapy for a variety of malignant and nonmalignant diseases. Allogeneic bone marrow transplantation from histocompatible donors is now ... Link to item Cite

Molecular characterization of MHC class II antigens (beta 1 domain) in the BB diabetes-prone and -resistant rat.

Journal article Immunogenetics · 1989 Featured Publication The BB or BB/Worcester (BB/W) rat is widely recognized as a model for human insulin-dependent diabetes mellitus (IDDM). Of at least three genes implicated in genetic susceptibility to IDDM in this strain, one is clearly linked to the major histocompatibili ... Full text Link to item Cite